InvestorsHub Logo
Followers 2
Posts 263
Boards Moderated 0
Alias Born 03/29/2017

Re: XenaLives post# 5301

Wednesday, 07/19/2017 2:07:33 PM

Wednesday, July 19, 2017 2:07:33 PM

Post# of 21531
Additional studies warranted
longer treatment duration
They cut the study in half!
Earlier stage disease
Well yes of course!
Optimal dose finding
Should be what a p2a is for!
Larger study to asses efficacy
a p2b/3!
Tragically failed study design to top it all
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News